Fewer patients on levetiracetam (14.4%) discontinued treatment because of adverse events compared with carbamazepine CR (19.2%), although this difference did not reach statistical significance.
1
—
—
Fewer patients on levetiracetam (14.4%) discontinued treatment because of adverse events compared with carbamazepine CR (19.2%), although this difference did not reach statistical significance.